Abstract:Joshua Bronte, 1 Crystal Zhou, 1 Abhinav Vempati, 1 Curtis Tam, 2 Jeffrey Khong, 3 Sanam Hazany, 1 Salar Hazany 1 1 Department of Research, Scar Healing Institute, Los Angeles, CA, USA; 2 Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 3 Department of Medicine, Johns Hopkins School of Medicine, Baltimore, MD, USA Correspondence: Joshua Bronte, Scar Healing Institute, Los Angeles, CA, USA, Tel +1 424 225 2453, Email Hypertrophic and keloid scars are fibroproliferative growths resulting from aberrant wound healing. Individuals with Fitzpatrick skin types (FSTs) IV–VI are particularly predisposed to hypertrophic and keloid scarring, yet specific guidelines for these populations are still lacking within the literature. Therefore, this comprehensive review provides a list of various treatments and considerations for hypertrophic and keloid scarring in patients with skin of color. We constructed a comprehensive PubMed search term and performed quadruple-blinded screening on all resulting studies to achieve this objective. Our findings demonstrate 1) the lack of efficacious treatments for raised scars within this population and 2) the need to empirically investigate individualized and multimodal therapeutic options for those with skin of color. Keywords: corticosteroid, bleomycin, 5-FU, laser, FST IV-VI, skin of color Hypertrophic scars (HTS) and keloids are two distinct types of scarring that clinically present as raised, firm, and reddened nodules or plaques at a site of previous skin trauma, often associated with pruritus or discomfort. 1,2 Their unique clinical and histopathological features can be explained by a variety of dysregulated extracellular matrix (ECM)-related and inflammatory processes that synergistically drive excess fibrosis. 2 At the cellular level, exaggerated proliferation of fibroblasts and their derivatives—notably myofibroblasts—participate directly in the excess deposition of dermal collagen during HTS and keloid formation. 3 Fibroblast and myofibroblast activities are driven by other key players in the keloid microenvironment, too, including type-1 and type-2 T-helper cells, M2 macrophages, dendritic cells, and natural killer cells. 3 Infiltration of these leukocytes contributes to a microenvironment enriched in inflammatory cytokines, notably transforming growth factor beta (TGF-β), interleukins, etc., which reciprocally upregulate the expression of pro-fibrotic genes. 4 They have also been understood to result from dysregulated inflammatory processes at the molecular level, which necessarily involves an anomalous response to the wound-healing process. 2 More specifically, it has been hypothesized that errors in the regulation of the inflammatory phase—the first of four stages in the wound-healing process—lead to the formation of these raised scars. 5–7 Excess levels of the pro-inflammatory cytokines IL-6 and IL-8 and insufficient levels of anti-inflammatory cytokine IL-10 have been implicated in skewing this wound-healing process towards excessive collagen deposition and fibrosis. 2 TGF-β also serves a key role in scar formation pathways. 2 This factor is a potent fibrogenic cytokine that directly stimulates fibroblasts to proliferate and increase the synthesis of extracellular matrix components, including collagen. 2 TGF-β1/2 are participatory members in a signaling cascade that leads to fibroblast activation; TGF-β3, unlike its counterparts, is a receptor antagonist in this process. 2 Increased fibroblast activation, due to over-expression of TGF-β1/2 and decreased expression of TGF-β3, leads to ECM collagen deposition, resulting in a hypertrophic or keloid scar response. 2 Despite their similar pathologic origins, HTS and keloids are pathologically distinct. Both types of scarring are classically characterized by their raised, indurated, and fibrotic features. 8 Although keloids have the ability to grow beyond the borders of the initial skin injury, hypertrophic scarring is often contained within the site of injury. 9 A histopathological comparative analysis demonstrated that keloid scars have a much more distinct distribution of fibroblasts and lymphocytes along their periphery, a characteristic underlying their persistent growth pattern. 10 Conversely, HTS have a less peripheral but more centralized fibroblast and lymphocytic infiltrate, which may explain their tendency to stagnate or regress. 10 Histologically, a pattern of wavy regularity has been observed in hypertrophic scarring; in contrast, keloid collagen composition is disorganized and demonstrates no repeated pattern. -Abstract Truncated-

A fast-switching diversity- and beam-forming-circuit for S-band satellite reception in fading scenarios

Clinical Applications of Basic Research That Shows Reducing Skin Tension Could Prevent and Treat Abnormal Scarring: the Importance of Fascial/subcutaneous Tensile Reduction Sutures and Flap Surgery for Keloid and Hypertrophic Scar Reconstruction.

Update on Hypertrophic Scar Management in Burn Patients

Hypertrophic Scars and Keloids: Advances in Treatment and Review of Established Therapies

Pharmacotherapy for Keloids and Hypertrophic Scars

Practical management of hypertrophic scarring: the mayo clinic experience

A Comprehensive Review of Non-Surgical Treatments for Hypertrophic and Keloid Scars in Skin of Color

Advanced wound management approaches in Hidradenitis Suppurativa postsurgical lesions

Transforming a Company, Project by Project: The IT Engagement Model

Traditional Chinese medicine for hypertrophic scars—A review of the therapeutic methods and potential effects

New Innovations in Scar Management

Preventive Effect of Hydrocolloid Dressings on Hypertrophic Scarring of Post-Cesarean Section Wounds: A Randomized Pilot Study

Combining scar-modulating agents for the treatment of hypertrophic scars and keloids: A systematic review

The Internet--a home care nursing clinical resource: Part I.

Hydrogel Loaded with Components for Therapeutic Applications in Hypertrophic Scars and Keloids

Lasers for the prevention and treatment of hypertrophic scars: a review of the literature

[Current methods of treatment and prevention of pathologic scars]

Involvement of norepinephrine in pituitary LH release induced by oestradiol in vitro.

Keloids and hypertrophic scars: update and future directions.

Portal vein grafts: microscopic study after a feven year follow-up.

Efficacy and safety of thermomechanical fractional injury-assisted corticosteroid delivery versus intralesional corticosteroid injection for the treatment of hypertrophic scars: A randomized split-scar trial